METHOD FOR REDUCING SUPERFICIAL OPHTHALMOAPPLICATOR DOSE IN CARRYING OUT INTRAOCULAR NEOPLASMS BRACHYTHERAPY Russian patent published in 2007 - IPC A61F9/00 A61K31/409 A61P43/00 A61N5/67 A61N5/10 

FIELD: medicine.

SUBSTANCE: method involves intravenously introducing chlorine row photosensitizer in pharmaceutical water-soluble dosage form at a dose of 0.7-1.05 mg/kg during 10 min. Fluorescent spectral diagnostic analysis of chlorine row photosensitizer accumulation is carried out in intraocular neoplasm in 1 h after having finished introduction. Neoplasm fluorescence being observed on the background of surrounding tissue, chlorine row photosensitizer in pharmaceutical liposome dosage form is introduced as intravenous bolus dose of 0.3-0.45 mg/kg. 10-15 min later after having finished the injection, laser radiation is applied tumor periphery is irradiated all over the whole tumor perimeter in transpupillary mode in laser radiation fields using wavelength of 670 nm with power density of 60-80 J/cm² with neighboring fields overlapping over 5% of area. Then the whole neoplasm surface is irradiated in transpupillary mode in laser radiation fields using wavelength of 662 nm with power density of 100-120 J/cm² with neighboring fields overlapping over 5% of area. Irradiation is carried out in circle moving from periphery towards the center. When calculating superficial ophthalmoapplicator dose in brachytherapy, initial tumor thickness is to be reduced by 4 mm.

EFFECT: enhanced effectiveness of treatment; reduced superficial ophthalmoapplicator dose; reduced risk of complications caused by radiation.